1. Home
  2. ARAY vs MGNX Comparison

ARAY vs MGNX Comparison

Compare ARAY & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Accuray Incorporated

ARAY

Accuray Incorporated

N/A

Current Price

$0.60

Market Cap

100.5M

Sector

Health Care

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$1.68

Market Cap

115.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARAY
MGNX
Founded
1990
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.5M
115.8M
IPO Year
2007
2013

Fundamental Metrics

Financial Performance
Metric
ARAY
MGNX
Price
$0.60
$1.68
Analyst Decision
Strong Buy
Hold
Analyst Count
2
5
Target Price
$3.50
$3.20
AVG Volume (30 Days)
782.5K
946.3K
Earning Date
02-04-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$436,969,000.00
$127,626,000.00
Revenue This Year
$3.82
N/A
Revenue Next Year
$4.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.99
52 Week High
$2.95
$3.02

Technical Indicators

Market Signals
Indicator
ARAY
MGNX
Relative Strength Index (RSI) 22.22 49.06
Support Level $0.56 $1.66
Resistance Level $0.83 $1.97
Average True Range (ATR) 0.05 0.12
MACD -0.01 -0.02
Stochastic Oscillator 17.06 29.58

Price Performance

Historical Comparison
ARAY
MGNX

About ARAY Accuray Incorporated

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: